SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue declined to Rs. 105.81 millions for the quarter ended June 2023 as compared to Rs. 106.41 millions during the corresponding quarter last year.The Net Loss for the quarter ended June 2023 is Rs. -53.32 millions as compared to Net Loss of Rs. -81.36 millions of corresponding quarter ended June 2022 Operating profit Margin for the quarter ended June 2023 improved to -25.82% as compared to -61.39% of corresponding quarter ended June 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 105.81 106.41 -0.56 105.81 106.41 -0.56 521.34 597.03 -12.68
Other Income 0.38 1.29 -70.54 0.38 1.29 -70.54 6.20 11.56 -46.37
PBIDT -25.82 -61.39 -57.94 -25.82 -61.39 -57.94 -151.59 -328.39 -53.84
Interest 10.97 3.04 260.86 10.97 3.04 260.86 29.73 53.91 -44.85
PBDT -36.79 -64.43 -42.90 -36.79 -64.43 -42.90 -181.32 -382.30 -52.57
Depreciation 16.53 16.93 -2.36 16.53 16.93 -2.36 65.59 62.97 4.16
PBT -53.32 -81.36 -34.46 -53.32 -81.36 -34.46 -246.91 -445.27 -44.55
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -53.32 -81.36 -34.46 -53.32 -81.36 -34.46 -246.91 -445.27 -44.55
Equity 215.61 215.61 0.00 215.61 215.61 0.00 215.61 215.61 0.00
PBIDTM(%) -24.40 -57.69 -57.70 -24.40 -57.69 -57.70 -29.08 -55.00 -47.14

Krebs Biochem.&Inds Share Price

60.90 -0.12 (-0.20%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×